echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Aceh Pharmaceutical Bcl-2 inhibitor APG-2575 is used to treat WM and is qualified as an FDA orphan drug.

    Aceh Pharmaceutical Bcl-2 inhibitor APG-2575 is used to treat WM and is qualified as an FDA orphan drug.

    • Last Update: 2020-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    WM is a lymphocyte tumor characterized by lymphatic plasma cells soaking the bone marrow and increasing the number of cloned immunoglobulin M (IgM) in the blood list.
    is a rare disease that accounts for less than 2% of non-Hodgkin's lymphoma patients in the United States.
    The objective remission rate (ORR) of WM's treatment options recommended in the current guidelines can reach 80%, but the deeper remission rate above good partial remission (VGPR) is very low (about 20% or less), and more patients will eventually relapse or progress.
    , the middle age of WM is around 70 years old, and the patient's physical condition is often insatiable with intense treatment.
    the improvement of WM therapeutic effect is an urgent clinical problem to be solved.
    . Datamonitor, Market Spotlight: WM published on April 17, 2020. Note: The original text is reduced.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.